HBeAg- serokonversion var øget hos patienter med forhøjede ALAT - niveauer; 77% (20/ 26) patienter, med præ- behandling ALAT > 2 x ULN, serokonverterede.
HBeAg seroconversion was increased in patients with elevated ALT levels; 77% (20/ 26) of patients with pre-treatment ALT > 2 x ULN seroconverted.